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While the crafting of a taxonomy scheme for laryngeal tumours might not seem to be so critical an endeavour, a well-constructed classification scheme actually serves as an essential foundation, allowing surgeons, pathologists and oncologists to use the same language for clarity and precision. As such, the classification of tumours is of considerable importance, and many attempts have been made to correlate the type of neoplasm with its biological behaviour. There are clinical, topographical and staging classifications and those based on the histological features of the individual neoplasms. The internationally applied TNM staging system is based on the anatomical extent of the respective tumours, but the histological features have been largely omitted. Early classifications were incomplete and too simple, only including a few types of malignant tumours, such as squamous cell carcinoma, undifferentiated carcinoma, adenocarcinoma and sarcomas. Histological classification of laryngeal neoplasms is of essential relevance to treatment planning and evaluation of prognosis but the frequently changing terminology may lead to misunderstandings and even mistakes.

The earliest tumour classification schemes relied upon the gross and/or light microscopic features of different tumour types. Presently, those classic gross and light microscopic differentiating features are being supplemented, or even replaced, by molecular features of the tumours themselves \[[@CR1], [@CR2]\].

In an early attempt at standardizing the nomenclature of laryngeal tumours, the World Health Organization (WHO) published its Histological Typing of Upper Respiratory Tract Tumours (which included the larynx) in 1978 \[[@CR3]\]. This classification was the result of a team effort by Drs. Shanmugaratnam and Sobin and pathologists from eight countries. The first version of this WHO classification is summarized in Table [1](#Tab1){ref-type="table"}.Table 1Histological typing of laryngeal tumours (1978)**Epithelial tumours**Benign Squamous cell papilloma/papillomatosis Oxyphilic adenoma (oncocytoma) OthersMalignant Carcinoma in situ (intraepithelial carcinoma) Squamous cell carcinoma Verrucous (squamous) carcinoma Spindle cell (squamous) carcinoma Adenocarcinoma Adenoid cystic carcinoma Carcinoid tumour Others Undifferentiated carcinoma**Soft tissue tumours**Benign Lipoma Haemangioma Leiomyoma Rhabdomyoma Granular cell tumour Neurofibroma Neurilemmoma (schwannoma) Paraganglioma (chemodectoma) OthersMalignant Fibrosarcoma Rhabdomyosarcoma Angiosarcoma Kaposi's sarcoma Others**Tumours of bone and cartilage**Benign Chondroma OthersMalignant Chondrosarcoma Others**Tumours of lymphoid and haemopoietic tissuesMiscellaneous tumoursSecondary tumoursUnclassified tumours**

The WHO classification of upper respiratory tract and ear tumours \[[@CR3]\] was reviewed by the following experts:

K. Shanmugaratnam (Singapore), L. H. Sobin (USA), L. Barnes (USA), A. Cardesa (Spain), A. Ferlito (Italy), I. Friedmann (England), D. K. Heffner (USA), H.B. Hellquist (Sweden), V. J. Hyams (USA), G.R.F. Krueger (Germany), C. Micheau (France) and A. Nascimento (Brazil). Several of these experts met in Dublin in 1988 and an amply illustrated, revised and updated second edition of the classification was published in 1991 \[[@CR4]\] (Table [2](#Tab2){ref-type="table"}).Table 2Histological typing of laryngeal tumours (1991)**Epithelial tumours and precancerous lesions**Benign Papilloma Papillomatosis Pleomorphic adenoma^a^ Basal cell (basaloid) adenoma^a^ Dysplasia and carcinoma in situ  Squamous cell dysplasia  Mild dysplasia  Moderate dysplasia  Severe dysplasia  Carcinoma in situMalignant Squamous cell carcinoma Verrucous squamous cell carcinoma Spindle cell carcinoma Adenoid squamous cell carcinoma^a^ Basaloid squamous cell carcinoma^a^ Adenocarcinoma Acinic cell carcinoma^a^ Mucoepidermoid carcinoma^a^ Adenoid cystic carcinoma Carcinoma in pleomorphic adenoma^a^ Epithelial-myoepithelial carcinoma^a^ Clear cell carcinoma^a^ Adenosquamous carcinoma^a^ Giant cell carcinoma^a^ Salivary duct carcinoma^a^ Carcinoid tumour Atypical carcinoid tumour^a^ Small cell carcinoma^a^ Lymphoepithelial carcinoma^a^**Soft tissue tumours**Benign Aggressive fibromatosis^a^ Myxoma^a^ Fibrous histiocytoma^a^ Lipoma Leiomyoma Rhabdomyoma Haemangioma Haemangiopericytoma^a^ Lymphangioma^a^ Neurilemmoma Neurofibroma Granular cell tumour ParagangliomaMalignant Fibrosarcoma Malignant fibrous histiocytoma^a^ Liposarcoma^a^ Leiomyosarcoma^a^ Rhabdomyosarcoma Angiosarcoma Kaposi\'s sarcoma Malignant haemangiopericytoma^a^ Malignant nerve sheath tumour^a^ Alveolar soft part sarcoma^a^ Synovial sarcoma^a^ Ewing sarcoma^a^**Tumours of bone and cartilage**Benign ChondromaMalignant Chondrosarcoma Osteosarcoma^a^**Malignant lymphomasMiscellaneous tumours**Benign Mature teratoma^a^Malignant Malignant melanoma^a^ Malignant germ cell tumours^a^**Secondary tumoursUnclassified tumours**^a^Oncotypes new to the second edition

In 2005 a third updated edition of the WHO Classification of Tumours was published, entitled Pathology and Genetics of Head and Neck Tumours \[[@CR5]\]. The larynx was included within Chapter 3 and was entitled "Hypopharynx, larynx and trachea" containing the following sections (Table [3](#Tab3){ref-type="table"}).Table 3Histological typing of laryngeal tumours (2005)**Malignant epithelial tumours**Squamous cell carcinomaVerrucous carcinomaBasaloid squamous cell carcinomaPapillary squamous cell carcinomaSpindle cell carcinomaAcantholytic squamous cell carcinomaAdenosquamous carcinomaLymphoepithelial carcinomaGiant cell carcinomaMalignant salivary gland-type tumoursNeuroendocrine tumours CarcinoidAtypical carcinoidSmall cell carcinoma, neuroendocrine type Combines small cell carcinoma, neuroendocrine type, with non-small cell carcinoma (squamous cell carcinoma, adenocarcinoma, etc.) Paraganglioma**Epithelial precursor lesionsBenign epithelial tumours**Papilloma/papillomatosisBenign salivary gland-type tumours**Malignant soft tissue tumours**FibrosarcomaMalignant fibrous histiocytoma (MFH)LiposarcomaLeomyosarcomaRhabdomyosarcomaKaposi\'s sarcomaPeripheral nerve sheath tumour (PNST)Synovial sarcoma**Inflammatory myofibroblastic tumourBenign soft tissue tumours**LipomaLeyomyomaHaemangioma and lymphangiomaGranular cell tumour**Haematolymphoid tumours**Non-Hodgkin lymphomaPlasmacytoma**Tumours of bone and cartilage**ChondrosarcomaOsteosarcomaChondromaGiant cell tumour**Mucosal malignant melanomaSecondary tumours**

A 4th edition WHO Classification of Tumours, entitled Pathology and Genetics of Head and Neck Tumours, was published in 2017 \[[@CR6]\]. The larynx was also included in Chapter 3, now entitled "Tumours of the hypopharynx, larynx, trachea and parapharyngeal space" (Table [4](#Tab4){ref-type="table"}).

Table 4Histological typing of laryngeal tumours (2017)**Malignant surface epithelial tumours**Conventional squamous cell carcinomaVerrucous squamous cell carcinomaBasaloid squamous cell carcinomaPapillary squamous cell carcinomaSpindle cell squamous cell carcinomaAdenosquamous carcinomaLymphoepithelial carcinoma**Precursor lesions**Dysplasia, low gradeDysplasia, high gradeSquamous cell papillomaSquamous cell papillomatosis**Neuroendocrine tumours**Well-differentiated neuroendocrine carcinomaModerately differentiated neuroendocrine carcinomaPoorly differentiated neuroendocrine carcinoma Small cell neuroendocrine carcinoma Large cell neuroendocrine carcinoma**Salivary gland tumours**Adenoid cystic carcinomaPleomorphic adenomaOncocytic papillary cystadenoma**Soft tissue tumours**Granular cell tumourLiposarcomaInflammatory myofibroblastic tumour**Cartilage tumours**ChondromaChondrosarcoma Chondrosarcoma grade 1 Chondrosarcoma grade 2/3**Haematolymphoid tumours**
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Considerations {#Sec2}
==============

The application of immunohistochemical methods, with an ever-increasing arsenal of antibodies and recently developed molecular biology techniques, will obviously enable a more accurate identification and therefore a more reliable classification of neoplasms of the larynx. In the latest 2017 WHO Classification of Head and Neck Tumours \[[@CR6]\], many of the laryngeal neoplasms described in the literature have been omitted. For example, only three salivary gland tumours are described, and acinic cell, salivary duct and myoepithelial carcinomas were not included. Similarly, unusual and rare tumours, such as NUT (nuclear protein in testis) midline carcinoma, synovial sarcoma, alveolar soft sarcoma and intestinal-type adenocarcinoma, are also not listed \[[@CR7]\]. Therefore, one has to refer to the earlier versions of the WHO Classification (2nd edition 1991 and 3rd edition 2005) to obtain a comprehensive view of the neoplasms that have been described in the larynx.

The histological classification is intended to facilitate the comparison of results in various fields of oncology and should be useful to pathologists, laryngologists, radiotherapists and oncologists as well as epidemiologists. A histological classification of neoplasms is extremely important for establishing a reliable prognosis, and this classification forms the foundation for appropriate clinical management of patients with laryngeal tumours.

Establishing the phenotype gives us a qualitative diagnosis of the disease. Different phenotypes have different biological behaviours, so only similar histopathological tumour types should be compared for their prognostic implications.

Specific histological types also give an indication of potential prognostic features. For example, small cell neuroendocrine carcinoma metastasizes more frequently than squamous cell carcinoma, which is in turn more aggressive than verrucous squamous cell carcinoma. These differences are further evidenced by the differing survival rates. The 5-year survival rates are approximately 68% for squamous cell carcinoma of the larynx \[[@CR8]\] and 5% for small cell neuroendocrine carcinoma \[[@CR9]\], considering all stages of the disease. Taking squamous cell carcinoma as a yardstick for comparison, verrucous squamous cell carcinoma, low-grade mucoepidermoid carcinoma, well-differentiated neuroendocrine carcinoma and chondrosarcoma all have a more favourable prognosis, whereas poorly differentiated neuroendocrine carcinoma (both small and large cell neuroendocrine carcinoma), moderately differentiated neuroendocrine carcinoma, NUT midline carcinoma and basaloid squamous carcinoma are likely to have a less favourable outcome.

If the histological type is properly identified, then specific and personalized tumour treatment protocols can be implemented. The phenotype should therefore be considered the most important factor in determining therapeutic decisions \[[@CR10], [@CR11]\]. In conclusion, confirming both the histological diagnosis and clinical characteristics of every tumour will form the basis for accurate, personalized and effective treatment planning.
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